A study recently published in the Journal of Neurology found that while more than half of patients with myasthenia gravis (MG) who achieved minimal manifestation or better status (MMS) eventually experience exacerbation, it was less likely in those with double-seronegative MG.
Recent therapeutic advancements have significantly improved patient outcomes in MG, with over 50% of patients achieving MMS, a clinical state in which disease activity has been reduced to a minimum. In MMS, there may be some muscle weakness, but there are no symptoms associated with MG and no functional limitations.
However, given the number of patients who experience exacerbations after achieving MMS, it is important for doctors to be able to identify patients at risk of exacerbation so that interventions can be initiated in a timely manner.
Chinese researchers conducted a study in which they reviewed the clinical records of 238 patients with a diagnosis of MG who have achieved MMS. Of these, 39 (16.4%) had double-seronegative MG, meaning they lacked serum antibodies against both acetylcholine receptors (AChRs ) and muscle-specific tyrosine kinase (MuSK). The other 199 (83.6%) had either anti-AChR or anti-MuSK antibodies.
In the overall cohort of patients, more than half had experienced an exacerbation. Approximately two-thirds (67.9%) of these exacerbations occurred within a 24-month period.
Read more about MG testing and diagnosis
Statistical analysis revealed that double seronegativity was a protective factor against MG exacerbations in patients who had achieved MMS. Among seronegative patients, those who hadn’t had a thymoma (thymus gland tumor) or a thymectomy to remove the thymus were less likely to expereince disease exacerbation.
“These findings suggest that double-seronegative MG may predict favorable clinical outcomes in both the MMS induction phase and the maintenance period,” the study’s wrote. “For these patients, balancing treatment benefits against adverse
effects throughout the course of the disease is essential.”
Sign up here to get the latest news, perspectives, and information about MG sent directly to your inbox. Registration is free and only takes a minute.
